Recombinant Human NKG2A/CD159a Fc Chimera Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Killer cell lectin like receptor C1 (KLRC1), also known as NKG2A/NKG2B type II integral membrane protein or NK cell receptor A, is a member of the C-type lectin family (1). The NKG2 family is comprised of three unique receptor isoforms, NKG2A, NKG2C and NKG2E, which regulate both inhibitory and activating signals and are attractive targets for immune-checkpoint inhibition (1-3). Mature human NKG2A consists of a cytoplasmic domain containing two immunoreceptor tyrosine based inhibitory motifs (ITIM), a helical type II transmembrane domain, and an extracellular domain (ECD) with a C-type lectin motif (4). Within the mature ECD, human NKG2A shares 41% and 45% amino acid sequence identity with mouse and rat NKG2A, respectively. NKG2A is an inhibitory member of the NKG2 family and is expressed on CD56high natural killer (NK) cells, natural killer T (NKT) cells and a subset of CD8+ alpha beta T cells. NKG2A forms a disulfide linked, dimeric complex with another C-type lectin, CD94 (KLRD1), and functions by binding with HLA-E, a non-classical MHC I molecule (1-4). The increased expression of NKG2A in tumor‑infiltrating NK cells is also emerging as a contributor in determining the poor prognosis of hepatocellular, lung or other carcinomas and in some cases may be a predictive factor of tumor metastasis (5). NKG2A immune checkpoint blockade in combination with PD-1/PD-L1 blockade or therapeutic cancer vaccines may hold promise in the treatment or multiple myeloma (MM) and various other solid and blood tumors or may improve the clinical outcome of patients who have undergone allogeneic hematopoietic stem cell transplantation (5-9).

Array 10511-NK

• NKG2A/CD159a/KLRC1 Antibodies
• NKG2A/CD159a/KLRC1 Lysates
• NKG2A/CD159a/KLRC1 Protein
• NKG2A/CD159a/KLRC1 Proteins and Enzymes